Market Research Logo

Liver Disease Treatments: The Global Market

Liver Disease Treatments: The Global Market

The global liver diseases therapeutics market totaled nearly $24.5 billion in 2014 and is projected to approach $33.8 billion by 2019, registering a compound annual growth rate (CAGR) of 6.7% through 2019.

This report provides:

An overview of the global market for liver disease treatment and related technologies.

Analyses of global market trends, with data from 2013 and 2014, and projections of compound annual growth rates (CAGRs) through 2019.

Information regarding market sizes, market leaders, market dynamics, and various other market factors, as well as the liver disease treatment market for end users.

Analysis of different liver disease drugs in response to an increasing need for new and innovative drug treatments.

Comprehensive profiles of major players as well as the acquisitions, mergers, and alliances by these companies and global organizations.


SCOPE OF THE STUDY

The scope of this study encompasses liver disease drug markets by various types. BCC Research analyzes each market by category with its applications in different regions of the world. It also analyzes the regulatory environment, technology and market projections. Application issues include the latest trends and developments in each liver disease drug category.

CHAPTER 1 INTRODUCTION
STUDY OBJECTIVES
REASON FOR DOING THIS STUDY
INTENDED AUDIENCE
SCOPE OF THE STUDY
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
CHAPTER 3 OVERVIEW
THE LIVER
DEFINITIONS
FUNCTIONS OF LIVER
PRODUCTION OF BILE
STORAGE OF FATS, CARBOHYDRATES, PROTEINS, VITAMINS, AND MINERALS
REGULATION OF NECESSARY SUBSTANCES IN THE BLOOD
SYNTHESIS OF COAGULATING PROTEINS
REMOVAL OF HARMFUL SUBSTANCES
OTHER FUNCTIONS
COMMON SYMPTOMS OF LIVER DISEASE
FATIGUE
JAUNDICE
SWOLLEN ABDOMEN
EFFECTS OF HORMONAL IMBALANCE
STOOL ABNORMALITIES
POLYDYPSIA AND POLYURIA
HEPATIC ENCEPHALOPATHY
SEXUAL DYSFUNCTION
NON-SPECIFIC SYMPTOMS OF LIVER DISEASE
LIVER DISEASE
TABLE 1 CLASSIFICATION OF LIVER DISEASE
TOXIC INJURY TO THE LIVER
Drug-induced Liver Disease
Industrial and Environmental Toxins
Alcohol-induced
Postoperative Hepatic Dysfunction
INFECTIOUS AGENTS AND PARASITES
Hepatitis Virus
Hepatitis A
Hepatitis B
Hepatitis C
Hepatitis D
Hepatitis E
Neonatal Hepatitis
Bacterial and Other Pathogenic Agents
Parasites
IMMUNE DISORDERS
Autoimmune Hepatitis
Primary Biliary Cirrhosis
TUMORS
Primary Malignant Tumors
Metastatic Malignant Tumors
Benign Hepatic Tumors
Tumor-like Lesions
INHERITED LIVER DISEASES
Wilson's Disease
Alagille Syndrome
Hemochromatosis
Inborn Errors
Alpha-1 Antitrypsin Deficiency
Cysts
Galactosemia
Gilbert's Syndrome
Tyrosinemia
MISCELLANEOUS DISEASES AND CONDITIONS
Non-alcoholic Fatty Liver Disease
Biliary Atresia
Cirrhosis
Hepatic Encephalopathy
Variceal Bleeding
Fatty Liver Disease
Gallstones
Reye's Syndrome
Sarcoidosis
CHAPTER 4 CLASSIFICATION OF THERAPIES BY DISEASE AND PRODUCTS ON THE MARKET
VIRUS-INDUCED LIVER DISEASE AND HEPATITIS
VIRAL VACCINES
TABLE 2 VACCINES FOR HEPATITIS A PREVENTION
TABLE 3 VACCINES FOR HEPATITIS B PREVENTION
ANTIVIRAL DRUGS
Nucleoside Analogs
TABLE 4 NUCLEOSIDE ANALOGS USED TO TREAT HEPATITIS
Nucleotide Analogs
TABLE 5 NUCLEOTIDE ANALOGS USED TO TREAT HEPATITIS
Interferon
TABLE 6 INTERFERONS USED TO TREAT HEPATITIS
Protease Inhibitors
TABLE 7 PROTEASE INHIBITORS USED TO TREAT HEPATITIS
Immunoglobulins
TABLE 8 IMMUNOGLOBULINS USED TO TREAT HEPATITIS
LIVER TUMORS AND LIVER CANCER
CHEMOTHERAPEUTIC DRUGS
TABLE 9 CHEMOTHERAPEUTIC DRUGS USED TO TREAT LIVER CANCER
TARGETED THERAPY
TABLE 10 TARGETED THERAPY USED TO TREAT LIVER CANCER
CONGENITAL LIVER DEFECTS
AUTOIMMUNE LIVER DISEASES
TABLE 11 DRUGS USED TO TREAT WILSON'S DISEASE
CORTICOSTEROIDS
TABLE 12 CORTICOSTEROIDS USED TO TREAT AUTOIMMUNE HEPATITIS
IMMUNOSUPPRESSIVE AGENTS
TABLE 13 IMMUNOSUPPRESSIVE AGENTS USED TO TREAT AUTOIMMUNE
HEPATITIS
ANTIMETABOLITES
TABLE 14 ANTIMETABOLITES USED TO TREAT AUTOIMMUNE HEPATITIS
ALCOHOL-INDUCED LIVER DISEASE
ANABOLIC STEROIDS
TABLE 15 ANABOLIC STEROIDS USED TO TREAT ALCOHOLIC LIVER DISEASE
ALCOHOL-ABUSE DRUGS
TABLE 16 ALCOHOL-ABUSE DRUGS USED TO TREAT ALCOHOLIC LIVER DISEASE
CHRONIC LIVER DISEASE
ANTI-REJECTION MEDICATIONS
TABLE 17 ANTI-REJECTION MEDICATIONS USED TO TREAT CHRONIC LIVER DISEASE
ANTI-INFECTIVES
TABLE 18 ANTI-INFECTIVES DRUGS USED TO TREAT CHRONIC LIVER DISEASE
ANTIFUNGAL PROPHYLAXIS
TABLE 19 ANTIFUNGAL PROPHYLAXIS FOR LIVER TRANSPLANT
RECIPIENTS
NON-ALCOHOLIC FATTY LIVER DISEASE
GALLSTONE-SOLUBILIZING AGENTS
TABLE 20 GALLSTONE-SOLUBILIZING AGENTS USED TO TREAT
NON-ALCOHOLIC FATTY LIVER DISEASE
OTHER DRUGS
TABLE 21 OTHER DRUGS USED TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE
CHAPTER 5 REGULATORY ASPECTS
TABLE 22 NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
TABLE 23 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER DISEASE, 2008-2013
FIGURE 1 NUMBER OF NEW APPROVALS FOR DRUGS USED TO TREAT LIVER
DISEASE, 2008-2013
TABLE 24 NEW DRUG APPLICATIONS, 2008-2013
TABLE 25 RECALLS, 2008-2014
CHAPTER 6 PREVALENCE
U.S.
TABLE 26 U.S. PREVALENCE OF LIVER DISEASE, 2000-2020 (NUMBER)
TABLE 27 U.S. HEPATITIS BURDEN, 2013 (NO. OF INFECTIONS)
EUROPE
REST OF THE WORLD
CHAPTER 7 MARKET BY DISEASE TYPE
TABLE 28 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, THROUGH 2019 ($ MILLIONS)
FIGURE 2 GLOBAL DRUG MARKET TO TREAT LIVER DISEASES BY DISEASE TYPE, 2012-2019 ($ MILLIONS)
HEPATITIS
TABLE 29 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 3 GLOBAL DRUG MARKET TO TREAT HEPATITIS BY REGION, 2012-2019 ($ MILLIONS)
HEPATOCELLULAR CARCINOMA
TABLE 30 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 4 GLOBAL DRUG MARKET TO TREAT HEPATOCELLULAR CARCINOMA BY REGION, 2012-2019 ($ MILLIONS)
AUTOIMMUNE LIVER DISEASES
TABLE 31 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 5 GLOBAL DRUG MARKET TO TREAT AUTOIMMUNE LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
ALCOHOL-INDUCED LIVER DISEASE
TABLE 32 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 6 GLOBAL DRUG MARKET TO TREAT ALCOHOL-INDUCED LIVER DISEASES BY REGION, 2012-2019 ($ MILLIONS)
CHRONIC LIVER DISEASE
TABLE 33 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 7 GLOBAL DRUG MARKET TO TREAT CHRONIC LIVER DISEASE BY REGION, 2012-2019 ($ MILLIONS)
NON-ALCOHOLIC FATTY LIVER DISEASE
TABLE 34 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, THROUGH 2019 ($ MILLIONS)
FIGURE 8 GLOBAL DRUG MARKET TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASE BY REGION, 20120-2019 ($ MILLIONS)
CHAPTER 8 PIPELINE
TABLE 35 CLINICAL TRIALS FOR LIVER DISEASES BY PHASE
TABLE 36 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY HASE
FIGURE 9 NUMBER OF CLINICAL TRIALS FOR LIVER DISEASES BY HASE
CHAPTER 9 DRUG-INDUCED LIVER DISEASE
TABLE 37 DRUGS THAT CAN CAUSE LIVER DISEASE
MAJOR DRUGS THAT CAN CAUSE LIVER DISEASE
ACETAMINOPHEN (TYLENOL)
STATINS
NICOTINIC ACID (NIACIN)
AMIODARONE (CARDARONE)
NITROFURANTOIN
AUGMENTIN
CHAPTER 10 CURRENT SITUATION AND FUTURE PROSPECTS
PREVALENCE AND LIFE EXPECTANCY
LACK OF EDUCATION AND LIMITED TREATMENT OPTIONS
RESEARCH AND DEVELOPMENT
LIVER ORGANIZATIONS
CHAPTER 11 PATENT ANALYSIS
TABLE 38 NUMBER OF U.S. PATENTS FOR DRUGS USED TO TREAT LIVER DISEASE BY COMPANY, 2012-NOVEMBER, 2014
TABLE 39 LIST OF PATENTS ISSUED, 2012-2014
TABLE 40 LIST OF PATENT APPLICATIONS, 2012-2014
CHAPTER 12 COMPANY PROFILES
ABBOTT LABORATORIES
ACHILLION PHARMACEUTICALS
ACTAVIS INC.
ALKERMES
ANTIPODEAN PHARMACEUTICALS
BAYER HEALTHCARE PHARMACEUTICALS
BIOTEST
BRISTOL-MYERS SQUIBB
CONATUS PHARMACEUTICALS
ELI LILLY
GALECTIN THERAPEUTICS
GILEAD SCIENCES INC.
GLAXOSMITHKLINE
GLOBEIMMUNE
GRIFOLS INTERNATIONAL
INTERCEPT PHARMACEUTICALS
ISIS PHARMACEUTICALS
KYOWA HAKKO KIRIN
MERCK & CO.
NOVARTIS
OCERA THERAPEUTICS INC.
PEREGRINE
PFIZER
ROCHE
ROXANE LABORATORIES
SALIX PHARMACEUTICALS
SCHERING PLOUGH CORP.
TAKEDA PHARMACEUTICAL
VALEANT PHARMACEUTICALS
VERTEX PHARMACEUTICALS INC.
XIAMEN AMOYTOP BIOTECH
ZYDUS PHARMACEUTICALS INC.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report